US · ENTO
Entero Therapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Boca Raton, FL 33431
- Website
- firstwavebio.com
Price · as of 2024-12-31
—
Market cap 20.11M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | $515,340.00 | ||||
| 2017 | $369,180.00 | ||||
| 2018 | $231,840.00 | ||||
| 2019 | $98,280.00 | ||||
| 2020 | $171,360.00 | ||||
| 2021 | $14,364.00 | ||||
| 2022 | $222.00 | ||||
| 2023 | $20.46 | ||||
| 2024 | $1.65 |
AI valuation
Our deep-learning model estimates Entero Therapeutics, Inc.'s (ENTO) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- —
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ENTO | Entero Therapeutics, Inc. | $4.22 | 20.11M | — | — | — | — | -0.43 | 0.13 | — | -491.36 | — | 0.14 | 0.00% | — | — | -58.82% | -0.05% | -39.13% | 0.00 | — | 3.03 | 0.01 | 1.47 | -8880.00% | — | -2842.00% | -119.84% | -0.33 | -31.51% | 0.00% | 0.00% | 0.00% | -490.90 | -0.83 | — | -2.37 |
| ALLR | Allarity Therapeutics, In… | $1.22 | 17.83M | — | — | — | — | -0.07 | 0.14 | — | 0.68 | — | 0.14 | 0.00% | — | — | -541.17% | 671.53% | -142.07% | 0.11 | -41.72 | 2.06 | 2.01 | 0.75 | -9974.00% | — | 3849.00% | -1036.16% | -1.60 | 441.86% | 0.00% | 0.00% | 1339.49% | 0.60 | 0.93 | — | -10.62 |
| ASBP | Aspire Biopharma Holdings… | $0.35 | 17.24M | — | — | — | — | -866.02 | -736.56 | — | -97.51 | — | -736.56 | 0.00% | — | — | -14.52% | -32.00% | -13.01% | -0.82 | 3.46 | 0.09 | 0.02 | -0.11 | -76087.00% | — | -5940.00% | -0.02% | -0.16 | -2.75% | 0.00% | 0.00% | 1.21% | -367.68 | -4282.42 | — | 295.56 |
| ATHA | Athira Pharma, Inc. | $4.19 | 16.53M | — | — | — | — | -0.14 | 0.29 | — | 0.38 | — | 0.29 | 0.00% | — | — | -110.77% | 967.28% | -88.52% | 0.03 | — | 4.18 | 3.90 | 0.49 | -1845.00% | — | -381.00% | -740.33% | -7.40 | 931.82% | 0.00% | 0.00% | 0.00% | 0.37 | 0.38 | — | -13.92 |
| BCTX | BriaCell Therapeutics Cor… | $10.22 | 19.25M | — | — | — | — | -0.64 | 0.95 | — | 0.03 | -1.44 | 0.96 | 0.00% | — | — | -343.04% | 1683.01% | -192.49% | 0.00 | -735.71 | 5.01 | 4.63 | 0.39 | 4450.00% | — | 1632.00% | -167.26% | -7.14 | 1742.76% | 0.00% | 0.00% | 56.64% | 0.03 | 0.03 | — | -8.16 |
| CING | Cingulate Inc. | $3.82 | 20.68M | — | — | — | — | -0.95 | 1.97 | — | -0.51 | — | 1.97 | 0.00% | — | — | -5305.02% | 1019.77% | -169.38% | 0.68 | — | 2.55 | 2.46 | 0.48 | -9673.00% | — | 2231.00% | -126.84% | -3.71 | 1216.50% | 0.00% | 0.00% | 71.84% | -0.49 | -0.41 | — | -11.88 |
| CRIS | Curis, Inc. | $1.42 | 17.75M | +255% | -18% | — | — | -0.42 | -3.06 | 1.68 | -0.03 | — | -1.23 | 99.10% | -408.34% | -397.77% | -634.71% | 156.53% | -73.20% | -0.49 | -72.43 | 1.39 | 1.23 | 0.40 | -2321.00% | 883.00% | 294.00% | -215.59% | -2.08 | 139.03% | 0.00% | 0.00% | 0.00% | -0.03 | -0.03 | 0.12 | -44.91 |
| CTXR | Citius Pharmaceuticals, I… | $1.37 | 15.31M | — | — | — | — | -0.33 | 0.19 | — | -0.28 | — | -0.38 | 0.00% | — | — | -57.75% | -58.28% | -32.10% | 0.03 | -143.87 | 0.62 | 0.09 | 0.06 | -4338.00% | — | -585.00% | -203.36% | -0.59 | -40.17% | 0.00% | 0.00% | 0.00% | -0.28 | -0.40 | — | -3.53 |
| LPTX | Leap Therapeutics, Inc. | $0.41 | 16.98M | — | — | — | — | -0.24 | 0.47 | — | 0.46 | — | 0.47 | 0.00% | — | — | -141.94% | 631.86% | -110.79% | 0.01 | — | 3.41 | 3.41 | 0.70 | -5452.00% | — | 3782.00% | -365.79% | -4.28 | 543.85% | 1.42% | -0.30% | 1.42% | 0.44 | 0.51 | — | -16.49 |
| PALI | Palisade Bio, Inc. | $1.68 | 15.33M | +46% | — | — | — | -0.08 | 0.16 | — | 0.59 | — | 0.16 | 0.00% | — | — | -153.55% | 1021.24% | -115.82% | 0.02 | -1238.25 | 3.24 | 3.04 | 0.67 | -6227.00% | -10000.00% | 948.00% | -1013.04% | -3.77 | 838.01% | 0.00% | 0.00% | 0.00% | 0.57 | 0.69 | — | -20.99 |
| PCSA | Processa Pharmaceuticals,… | $0.34 | 17.12M | — | — | — | — | -0.12 | 0.87 | — | -0.03 | — | 0.87 | 0.00% | — | — | -354.51% | -2381.97% | -262.87% | 0.04 | — | 1.22 | 0.78 | 0.09 | -5436.00% | — | 3945.00% | -761.08% | -7.34 | -2223.27% | 0.00% | 0.00% | 1.08% | -0.03 | -0.03 | — | -49.42 |
About Entero Therapeutics, Inc.
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides; biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; capeserod, a selective 5-HT4 receptor partial agonist to treat gastroparesis; and niclosamide, an oral small molecule with anti-inflammatory properties for patients with inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease. It is also developing CypCel, a disease management tool for monitoring the intestinal health of recovering celiac disease patients. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.
- CEO
- Richard Joel Paolone
- Employees
- 2
- Beta
- 1.19
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ —) − 1 = — (DCF, example).